<code id='EAFCEC6DA9'></code><style id='EAFCEC6DA9'></style>
    • <acronym id='EAFCEC6DA9'></acronym>
      <center id='EAFCEC6DA9'><center id='EAFCEC6DA9'><tfoot id='EAFCEC6DA9'></tfoot></center><abbr id='EAFCEC6DA9'><dir id='EAFCEC6DA9'><tfoot id='EAFCEC6DA9'></tfoot><noframes id='EAFCEC6DA9'>

    • <optgroup id='EAFCEC6DA9'><strike id='EAFCEC6DA9'><sup id='EAFCEC6DA9'></sup></strike><code id='EAFCEC6DA9'></code></optgroup>
        1. <b id='EAFCEC6DA9'><label id='EAFCEC6DA9'><select id='EAFCEC6DA9'><dt id='EAFCEC6DA9'><span id='EAFCEC6DA9'></span></dt></select></label></b><u id='EAFCEC6DA9'></u>
          <i id='EAFCEC6DA9'><strike id='EAFCEC6DA9'><tt id='EAFCEC6DA9'><pre id='EAFCEC6DA9'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          leisure time

          author:Wikipedia    - browse:42234
          Franklin faces
          Adobe

          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

          advertisement

          Arch declined to comment on the new fundraising.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus